WAVE Life Sciences Ltd. (WVE: NASDAQ) Investor Relations Material

Overview

Singapore-based Wave Life Sciences Ltd., a clinical-stage genetic medicine company, has developed a discovery and drug development platform called PRISM which enables it to design, optimize, and produce stereopure oligonucleotides. These oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore functional proteins production, or reduce the expression of disease-promoting RNAs or proteins. The company is working on a number of molecules including WVE-004 for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia, WVE-003 for the treatment of Huntington's disease and WVE-N531 for the treatment of Duchenne muscular dystrophy. Furthermore, it has several preclinical programs for CNS-related disorders, such as Alzheimer's and Parkinson's diseases. The company has also established collaboration agreements with Pfizer, Takeda Pharmaceutical Company, and Glaxo Group. Wave Life was incorporated in 2012.